🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMASH / Liver DiseaseHas anyone dealt with glp-1 hepatoprotection? Page 5

Has anyone dealt with glp-1 hepatoprotection?

GenomicsKate Fri, Jul 11, 2025 at 12:32 PM 33 replies 1,678 viewsPage 5 of 7
Dr.EndoEP
Member
267
1,234
Oct 2024
El Paso, TX
Jul 17, 2025 at 2:38 PM#21
DanielChem_CHI said:
Give anything pharmacological four weeks before you judge it, and give anything measured weekly a four-point rolling average before you call it a…

That reframing is the part I needed.

Last edited: Jul 17, 2025 at 4:38 PM
34 7NicoleRaleigh, james_edin, FranDenver and 31 others
Reply Quote Save Share Report
PeptideChemSF
Senior Member
1,890
9,012
Jan 2024
San Francisco, CA
Jul 19, 2025 at 7:46 AM#22

Adding the clinical framing, because it changes how the question reads. Take it one variable at a time. Almost every unanswerable question in these threads is unanswerable because three things changed in the same fortnight, and no amount of subsequent argument can untangle them after the fact.

35 8dave_SLC, FDA_TrackerJim, ricardo_MIA and 32 others
Reply Quote Save Share Report
traveltech_sara
Member
156
678
Jan 2025
Remote, USA
Jul 21, 2025 at 12:53 AM#23
PeptideChemSF said:
Almost every unanswerable question in these threads is unanswerable because three things changed in the same fortnight, and no amount of subsequent…

Can confirm. Same sequence, different timescale. The detail I would add is minor and it is already implied above.

36 9wanda_boise, NurseAsh_DET, BenResearch_OR and 33 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
Dr.AddMedPHL
Senior Member
1,234
6,234
Mar 2024
Philadelphia, PA
Jul 22, 2025 at 5:59 PM#24
PeptideChemSF said:
Almost every unanswerable question in these threads is unanswerable because three things changed in the same fortnight, and no amount of subsequent…

There is a second half to this that has not been said yet. Whatever the answer turns out to be, the method for getting there is the same: state the assumption, do the arithmetic in public, and invite the correction. That is slower than asserting, and it is the only version that survives being wrong.

Last edited: Jul 22, 2025 at 7:59 PM
37 10TomFromTexas, mike.trainer_LA, sarah_nash92 and 34 others
Reply Quote Save Share Report
DoseLogDan
Member
201
567
Feb 2025
Montana
Jul 24, 2025 at 11:04 AM#25

The figures, for anyone assembling their own picture. If you are comparing against somebody else’s result, check that you are comparing the same measurement taken the same way. Most of the apparent contradictions in these threads dissolve at that step.

38 11carlos_SATX, sophie_paris, mel_PDX and 35 others
Reply Quote Save Share Report

Similar Threads

Survodutide MASH Phase 2b — histological improvement data9 replies
Semaglutide and MASH — liver fat reduction quantification13 replies
Non-invasive MASH biomarkers — FibroScan, ELF, FIB-4 on GLP-110 replies
ALT normalization rates on GLP-1 — pooled trial data20 replies
GLP-1 hepatoprotection — direct vs indirect mechanisms16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register